IGF-IIsT, therefore, includes the smaller group formerly defined as IGF2omas and further extends to all IGF-II-bearing autocrine loop-positive cancers, as confirmed via (a) histopathological or other protein-positional pathology detection/imaging methods, (b) transcript (RNAseq) or protein (mass-spectrometry-based) panels in patient-derived circulating tumor cells (CTCs), or (c) IGF-II-neutralizing antibody-inhibited cultural growth of patient primary cells or CTC cultures. The gene discussed is IGF2; the disease is cancer.